Hansa Medical's Nomination Committee for the AGM 2019 Appointed and 2019 Financial Calendar Published
Lund, Sweden, October 25, 2018 - Hansa Medical AB (Nasdaq Stockholm: HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced the appointment of the Nomination Committee for the Annual General Meeting (AGM) 2019 and the publication of the 2019 financial calendar.
In accordance with the decision of the AGM on May 29, 2018, a Nomination Committee for the Hansa Medical AGM 2019 has been formed. Based on the list of shareholders as of 31 August 2018, the three largest shareholders have been contacted and invited to each appoint a representative to the Nomination Committee. The Nomination Committee consists of Erika Kjellberg Eriksson representing Nexttobe AB, Astrid Samuelsson representing Handelsbanken Funds, Sven Sandberg representing Thomas Olausson and Gladiator. The Nomination Committee also includes the chairman of the board, Ulf Wiinberg, as convener.
The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and the auditors and proposals for rules for the Nominating Committee for the AGM in 2019.
The AGM of Hansa Medical AB (publ) will be held May 22, 2019 in the Auditorium (Hörsalen) by the Company's premises at Scheelevägen 22 in Lund.
Shareholders wishing to submit comments or proposals to the Nomination Committee may do so no later than March 27, 2019 via e-mail to email@example.com or by letter to Hansa Medical, Nomination Committee, Box 785, 220 07 Lund, Sweden. The Nomination Committee's proposals will be presented in the notice convening the AGM and on the Company's website.
Year-end report 2018, 8 February 2019
Annual report 2018, 15 April 2019
Interim report for January – March 2019, 29 April 2019
Annual General Meeting 22 May, 2019
Interim report for January – June 2019, 18 July 2019
Interim report for January – September 2019, 31 October 2019
The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on October 25, 2018.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477
Swedish Investor and Media Relations:
+46 70-311 99 60
U.K. Investor and Media Relations
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Stephanie Marks/ David Rosen (media)
+1 212 600 1902
About Hansa Medical
Hansa Medical (Nasdaq Stockholm: HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, imlifidase, is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin-cleaving enzymes are developed for repeat dosing with the objective of applying the Hansa Medical technology in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on Nasdaq Stockholm.